JEFF believe gene-editing technologies going to transform medical treatments for diverse diseases;current leaders in gene-editing are platform plays, reminiscent of where $ALNY was 2012-2013 $KITE $CELG were in 2015-2016 –current valuations for $NTLA $C

JEFF believe gene-editing technologies going to transform medical treatments for diverse diseases;current leaders in gene-editing are platform plays, reminiscent of where $ALNY was 2012-2013 $KITE $CELG were in 2015-2016 –current valuations for $NTLA $CRSP do not reflect potentia

More From BioPortfolio on "JEFF believe gene-editing technologies going to transform medical treatments for diverse diseases;current leaders in gene-editing are platform plays, reminiscent of where $ALNY was 2012-2013 $KITE $CELG were in 2015-2016 –current valuations for $NTLA $C"